Vosevi OverviewVoxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017. On 18 July 2017, Vosevi was approved by Food and drug administration. References ^ "voxilaprevir_msds". ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 20...
Read more Vosevi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Voxilaprevir
Recent Vosevi Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
Sofosbuvir + Velpatasvir + Voxilaprevir
- Tablet: 400mg + 100mg + 100mg
NDC Database Records for Vosevi: (1 result)Sorted by National Drug Code
- 61958-2401 Vosevi Oral Tablet, Film Coated by Gilead Sciences, Inc.